Cancer drug development in Europe: A selection of new agents under development at the European Drug Development Network

D. Lacombe, A. Butler-Smith, P. Therasse, P. Fumoleau, S. Burtles, H. Calvert, S. Marsoni, C. Sessa, J. Verweij

Research output: Contribution to journalArticle

Abstract

From may 99, three european leaders in anti-cancer drug development (EORTC, Cancer Research UK, SENDO) have got together to form a network of collaborating groups: the European Drug Development Network. The member organisations have all agreed to join their efforts in developing new drugs. They have acquired a great and efficient expertise in anticancer drug development covering all aspects from drug screening to refinement of trial methodology and translational research. In this paper, the most interesting drugs under development in each of the three organisations are being described and discussed.

Original languageEnglish
Pages (from-to)137-147
Number of pages11
JournalCancer Investigation
Volume21
Issue number1
DOIs
Publication statusPublished - 2003

Keywords

  • Cancer research
  • Clinical trials
  • European Drug Development Network
  • New drugs

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Cancer drug development in Europe: A selection of new agents under development at the European Drug Development Network'. Together they form a unique fingerprint.

  • Cite this

    Lacombe, D., Butler-Smith, A., Therasse, P., Fumoleau, P., Burtles, S., Calvert, H., Marsoni, S., Sessa, C., & Verweij, J. (2003). Cancer drug development in Europe: A selection of new agents under development at the European Drug Development Network. Cancer Investigation, 21(1), 137-147. https://doi.org/10.1081/CNV-120016408